BioVersys' BV100 Phase 2B Study Set for Asia

BioVersys AG has announced the commencement of its BV100 Phase 2B trial through the Wellcome-funded ADVANCE-ID network, alongside the National University of Singapore. BV100, an anti-infective targeting hospital infections caused by Acinetobacter baumannii, stands out after selection over 24 other candidates. The trial, bolstered by non-dilutive funding of SGD 22 million, aims to include 90 patients across Southeast Asia in a clinical study expected to unfold in 2026.

This collaborative effort aims to provide additional clinical data for BV100's new drug application and demonstrate its effectiveness against carbapenem-resistant strains in environments with high drug resistance. The trial will feature three treatment arms, comparing BV100's efficacy with recently approved drugs. Interim results are anticipated in the latter half of 2026.